(secondQuint)Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation.

 This is a follow-up study to investigate the change of immunogenicity and lesion condition in subjects with cervical intraepithelial neoplasia (CIN) 3 who have enrolled and completed GX-188E phase I study.

 Subjects will make visits at week 48 (V1) to week 228 (V8) every 6 months after the final administration of GX-188E.

 The endpoints are to evaluate the change of immune response, involved lesion and infection status compared to that of the final visit in phase I study.

.

 Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation@highlight

This study is to follow up on the change of immune response by measuring HPV type 16/18 E6 and E7 specific T cell response and lesion condition in subjects who have administered in DNA-based therapeutic vaccine.

